Douglas R Hurst

List of Publications by Year in Descending Order

43 papers	2,239 citations	23 h-index	47 g-index
48 ext. papers	2,566 ext. citations	7 avg, IF	5.2 L-index

#	Paper	IF	Citations
43	Perturbation of BRMS1 interactome reveals pathways that impact metastasis. *PLoS ONE*, **2021**, 16, e0259128	3.7	
42	miR-31 Displays Subtype Specificity in Lung Cancer. *Cancer Research*, **2021**, 81, 1942-1953	10.1	1
41	Re-expression of DIRAS3 and p53 induces apoptosis and impaired autophagy in head and neck squamous cell carcinoma. *Military Medical Research*, **2020**, 7, 48	19.3	4
40	Defining the Hallmarks of Metastasis. *Cancer Research*, **2019**, 79, 3011-3027	10.1	194
39	Increased autophagic response in a population of metastatic breast cancer cells. *Oncology Letters*, **2016**, 12, 523-529	2.6	1
38	SIN3A and SIN3B differentially regulate breast cancer metastasis. *Oncotarget*, **2016**, 7, 78713-78725	3.3	20
37	Globular adiponectin enhances invasion in human breast cancer cells. *Oncology Letters*, **2016**, 11, 633-641	1.6	17
36	Promising oncolytic agents for metastatic breast cancer treatment. *Oncolytic Virotherapy*, **2015**, 4, 63-736		8
35	SOCS3 Deficiency in Myeloid Cells Promotes Tumor Development: Involvement of STAT3 Activation and Myeloid-Derived Suppressor Cells. *Cancer Immunology Research*, **2015**, 3, 727-40	12.5	37
34	Linking adiponectin and autophagy in the regulation of breast cancer metastasis. *Journal of Molecular Medicine*, **2014**, 92, 1015-23	5.5	15
33	Expression of metastasis suppressor BRMS1 in breast cancer cells results in a marked delay in cellular adhesion to matrix. *Molecular Carcinogenesis*, **2014**, 53, 1011-26	5	13
32	Histone deacetylase inhibitors improve the replication of oncolytic herpes simplex virus in breast cancer cells. *PLoS ONE*, **2014**, 9, e92919	3.7	38
31	Unraveling the XTGF-□paradoxXone metastamir at a time. *Breast Cancer Research*, **2013**, 15, 305	8.3	5
30	The C-terminal putative nuclear localization sequence of breast cancer metastasis suppressor 1, BRMS1, is necessary for metastasis suppression. *PLoS ONE*, **2013**, 8, e55966	3.7	15
29	Mitochondrial bioenergetics of metastatic breast cancer cells in response to dynamic changes in oxygen tension: effects of HIF-1□*PLoS ONE*, **2013**, 8, e68348	3.7	24
28	Ubiquitous Brms1 expression is critical for mammary carcinoma metastasis suppression via promotion of apoptosis. *Clinical and Experimental Metastasis*, **2012**, 29, 315-25	4.7	11
27	Metastasis suppression by BRMS1 associated with SIN3 chromatin remodeling complexes. *Cancer and Metastasis Reviews*, **2012**, 31, 641-51	9.6	20

26	Clinical significance of KISS1 protein expression for brain invasion and metastasis. *Cancer*, **2012**, 118, 2096-105	6.4	21
25	Protein Signatures in Human MDA-MB-231 Breast Cancer Cells Indicating a More Invasive Phenotype Following Knockdown of Human Endometase/Matrilysin-2 by siRNA. *Journal of Cancer*, **2011**, 2, 165-76	4.5	6
24	Metastasis suppressors and the tumor microenvironment. *Seminars in Cancer Biology*, **2011**, 21, 113-22	12.7	46
23	Unraveling the enigmatic complexities of BRMS1-mediated metastasis suppression. *FEBS Letters*, **2011**, 585, 3185-90	3.8	31
22	Gli1 enhances migration and invasion via up-regulation of MMP-11 and promotes metastasis in ER negative breast cancer cell lines. *Clinical and Experimental Metastasis*, **2011**, 28, 437-49	4.7	53
21	Metastasis suppressor genes at the interface between the environment and tumor cell growth. *International Review of Cell and Molecular Biology*, **2011**, 286, 107-80	6	104
20	Heparanase-mediated loss of nuclear syndecan-1 enhances histone acetyltransferase (HAT) activity to promote expression of genes that drive an aggressive tumor phenotype. *Journal of Biological Chemistry*, **2011**, 286, 30377-30383	5.4	86
19	Metastamir: the field of metastasis-regulatory microRNA is spreading. *Cancer Research*, **2009**, 69, 7495-8	10.1	257
18	Breast cancer metastasis suppressor 1 coordinately regulates metastasis-associated microRNA expression. *International Journal of Cancer*, **2009**, 125, 1778-85	7.5	71
17	Multiple forms of BRMS1 are differentially expressed in the MCF10 isogenic breast cancer progression model. *Clinical and Experimental Metastasis*, **2009**, 26, 89-96	4.7	28
16	Nuclear magnetic resonance and circular dichroism study of metastin (Kisspeptin-54) structure in solution. *Clinical and Experimental Metastasis*, **2009**, 26, 527-33	4.7	4
15	Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. *Cancer Research*, **2009**, 69, 1279-83	10.1	338
14	Over-expression of the BRMS1 family member SUDS3 does not suppress metastasis of human cancer cells. *Cancer Letters*, **2009**, 276, 32-7	9.9	15
13	Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone. *Oncology Reports*, **2009**, 21, 761-7	3.5	98
12	BRMS1 suppresses breast cancer experimental metastasis to multiple organs by inhibiting several steps of the metastatic process. *American Journal of Pathology*, **2008**, 172, 809-17	5.8	81
11	Alterations of BRMS1-ARID4A interaction modify gene expression but still suppress metastasis in human breast cancer cells. *Journal of Biological Chemistry*, **2008**, 283, 7438-44	5.4	59
10	Breast cancer metastasis suppressor-1 differentially modulates growth factor signaling. *Journal of Biological Chemistry*, **2008**, 283, 28354-60	5.4	41
9	Requirement of KISS1 secretion for multiple organ metastasis suppression and maintenance of tumor dormancy. *Journal of the National Cancer Institute*, **2007**, 99, 309-21	9.7	131

8	Matrix metalloproteinase inhibitors as prospective agents for the prevention and treatment of cardiovascular and neoplastic diseases. *Current Topics in Medicinal Chemistry*, **2006**, 6, 289-316	3	94
7	Breast cancer metastasis suppressor 1 (BRMS1) is stabilized by the Hsp90 chaperone. *Biochemical and Biophysical Research Communications*, **2006**, 348, 1429-35	3.4	61
6	Suppression of murine mammary carcinoma metastasis by the murine ortholog of breast cancer metastasis suppressor 1 (Brms1). *Cancer Letters*, **2006**, 235, 260-5	9.9	25
5	Inhibition of enzyme activity of and cell-mediated substrate cleavage by membrane type 1 matrix metalloproteinase by newly developed mercaptosulphide inhibitors. *Biochemical Journal*, **2005**, 392, 527-36	3.8	19
4	Catalytic- and ecto-domains of membrane type 1-matrix metalloproteinase have similar inhibition profiles but distinct endopeptidase activities. *Biochemical Journal*, **2004**, 377, 775-9	3.8	43
3	The intermediate S1Xpocket of the endometase/matrilysin-2 active site revealed by enzyme inhibition kinetic studies, protein sequence analyses, and homology modeling. *Journal of Biological Chemistry*, **2003**, 278, 51646-53	5.4	42
2	Protein engineering and properties of human metalloproteinase and thrombospondin 1. *Biochemical and Biophysical Research Communications*, **2002**, 293, 478-88	3.4	11
1	Development and characterization of a new polyclonal antibody specifically against tissue inhibitor of metalloproteinases 4 in human breast cancer. *Biochemical and Biophysical Research Communications*, **2001**, 281, 166-71	3.4	13